Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam

Abstract

Objective: This study aimed to analyze the treatment outcome and toxicities, along with prognosis factors of patients with FIGO 2018 stage III cervical cancer treated with definitive concurrent chemoradiation. Methods: A total of 83 stage III cervical cancer patients with good performance status (ECOG PS 0, 1) were treated with three-dimensional conformal radiation therapy (3D-CRT) combined with chemotherapy (weekly cisplatin), followed by high-dose-rate (HDR) brachytherapy between January 2017 and March 2019 at Vietnam National Cancer hospital. Treatment outcomes and prognosis factors were assessed along with acute and late toxicities. Results: The 3-year DFS was 67.8% and 3-year OS was 80.3%. On multivariate analyses, short axis of pelvic lymph node diameter of ≥ 15mm, invasion of the lower third of vagina and para-aortic lymph node metastasis were identified as adverse prognostic factors for DFS. The cumulative incidence rate of gastrointestinal and genitourinary toxicity (≥ grade 2) at the 3-year follow-up were 29.6% and 11.6%, respectively. Conclusions: 3D CRT and HDR brachytherapy with concurrent chemotherapy is an effective treatment, with acceptable toxicity for FIGO 2018 stage III cervical cancer in Vietnam.

Incidence, Treatment and Outcomes of Cervical Cancer in Low- and Middle-income Countries

“…At 3 years, the local control rate was 89.5e94.4%. At 3 years, DFS was 63.4e81.8% and overall survival was 64.6e89.5% [53,54]. Most of the published literature mentioned are from Thailand and China.…”

Curative treatment for stage IIIC2 cervical cancer: what to expect?

“…Back in 1981, Piver et al [ 24 ] published American results on this matter with technology for diagnosis and treatment suitable for that era. More recently, other countries have also published their results, including a Vietnamese [ 25 ], Turkish [ 26 ], Japanese [ 27 ] and Chinese [ 28 ] study, all of them with samples smaller than the one presented here. Specifically, regarding Liu et al (2019) [ 28 ], that reported the outcomes of a number of patients (59) similar to our study (65), the three-year overall survival of 52.8% was comparable with 50.6% finding in our cohort.…”